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Background:  Previous studies confirmed Cheyne-Stokes respiration (CSA) to be associated with pulmonary congestion and elevated 
pulmonary capillary wedge pressure (PCWP) in chronic heart failure (CHF). This study aimed to investigate if acute improvement of 
pulmonary congestion impacts CSA severity.
methods:  21 consecutive patients with CHF and CSA (apnea-hypopnea-index (AHI)≥15/h) underwent right heart catheterization. 
Glyceryltrinitrate (GTN, starting with 2mg/h, increased by 2mg/h every 5 minute) was infused i. v. to a maximum tolerable dosage. After a 
15min wash-out phase, inhalation of 10mcg/ml Iloprost was performed. Maximum tolerable
dosages of GTN and Iloprost were randomly applied during full cardiorespiratory polysomnography within 2 split-night procedures versus 
i.v. or inhalative NaCl 0.9%, respectively.
results:  GTN (6.2±1.5mg/h) and Iloprost significantly lowered mean pulmonary artery pressure (mPAP; 20.1±9.0 to 11.6±4.2mmHg, 
p<0.001 and 16.9±7.9 to 14.2±6.4mmHg, p<0.01, respectively. PCWP was lowered by GTN (14.0±5.6 to 7.2±3.9mmHg, p<0.001) 
exclusively, while Iloprost had no significant effect. Sleep studies results are displayed below. 
Parameter Glyceryltrinitrate Placebo P Iloprost Placebo P
central apnea, h-1 14.4 ± 16.5 11.5 ± 16.3 0.09 13.1 (10.3, 16.0) 13.0 (11.1, 17.0) 0.56
apnea+hypopnea total, h-1 39.0 ± 17.7 35.3 ± 15.3 0.33 34.9 ± 21.9 33.3 ± 19.4 0.55
time sO2 < 90%, % 23.3 ± 28.8 10.9 ± 14.4 0.03 3.0 (0.3, 16.2) 1.5 (0.0, 11.1) 0.31
cycle length, s 48.4 ± 10.6 49.6 ± 11.0 0.13 48.0 ± 2.5 46.9 ± 2.7 0.44
ventilation length, s 30.5 ± 7.3 30.6 ± 8.1 0.83 30.1 ± 7.9 29.8 ± 8.1 0.81
apnea length, s 17.9 ± 3.9 19.0 ± 3.6 0.47 17.9 ± 3.1 17.1 ± 3.9 0.24
circulatory delay, s 34.4 ± 7.4 34.6 ± 12.2 0.85 31.8 ± 8.6 32.9 ± 8.4 0.44
time to peak ventilation, s 14.2 ± 3.2 14.5 ± 4.5 0.73 13.8 ± 3.8 13.2 ± 3.8 0.48
total sleep time, min 174 (144, 197) 176 (152, 198) 0.98 175 ± 27 171 ± 33 0.76
S1 stadium/total sleep time, % 34 ± 23 19 ± 21 0.02 17 (12, 22) 18 (13, 25) 0.98
S2 stadium/total sleep time, % 41 ± 19 36 ± 14 0.12 39 ± 14 37 ± 13 0.57
S3 stadium/total sleep time, % 18 ± 17 34 ± 15 <0.001 31 ± 17 31 ± 16 0.50
REM sleep/total sleep time, % 7 ± 7 10 ± 7 0.06 12 ± 9 12 ± 7 0.95
arousals/total sleep time, n 33 ± 11 25 ± 7 <0.01 25 ± 13 27 ± 12 0.28
conclusion:  Acute improvement of pulmonary congestion by GTN had no immediate impact on CSA severity. Extended treatment periods, 
attenuation of deranged chemoreflex cascades, and normal sleep patterns appear crucial for successful, causal therapies.
